Comparison Chart Madrigal Pharmaceuticals, Inc.
Stocks
MDGL
US5588681057
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 507.56 USD | +5.30% |
|
-7.93% | -12.84% |
| 07-30 | Madrigal Pharmaceuticals Q2 Loss Widens, Revenue Increases | MT |
| 07-30 | Madrigal Pharmaceuticals, Inc., Q2 2026 Earnings Call, Jul 30, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Bio Therapeutic Drugs | +5.30% | -7.93% | -12.84% | +67.97% | +494.40% | 11.14B |  |  | |
- Stock Market
- Stocks
- MDGL Stock
- Charts Madrigal Pharmaceuticals, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
